Gyros® AB, the leading provider of automated micro-immunoassays for therapeutic protein development, is pleased to announce the sale of a fifth Gyrolab® system to MedImmune. This additional system will be installed at the company's Hayward facility. Previously installed Gyrolab systems are in use at MedImmune's facilities in Gaithersburg, USA and Cambridge, UK.
"Not only is this a huge vote of confidence that Gyrolab continues to add significant value to the drug discovery and development workflow but it also underlines a trend that is evident within the industry," stated Erik Walldén, CEO and president of Gyros. "We are seeing that it's actually the biotech companies - like MedImmune, Amgen and ThromoboGenics all with multiple systems - who are leading the way by implementing Gyrolab to shorten project times, increase efficiency and increase their competiveness in the race to deliver new protein-based therapeutics. These organizations understand that the added benefits that Gyrolab delivers are vital to become more productive."
"The key reasons for the purchase of the existing systems within the MedImmune organization have been the high throughput and reduced reagent consumption. Gyrolab reduces turnaround time so that critical decisions can be taken earlier in the process," as stated in an earlier interview with MedImmune. Visit www.gyros.com/endorsements for full details.
"Critical factors in this recent purchase by the Hayward facility were the extremely small sample volumes required, as little as 10 microliters, and the very broad dynamic range. Both crucial in the clinical phase of drug development," adds Katherine Flagg VP Sales, North America at Gyros Inc.
For further information, please contact:
Erik Walldén, CEO
Tel: +46 18-56 64 00
Linda van Manen, BGA Group
Tel: +31 78 631 97 15
Notes to editors:
About Gyros AB
Gyros is the world leader in automated micro-immunoassays for therapeutic protein development.
Gyrolab, the company's automated and open platform, is a versatile analytical tool that dramatically reduces the time required to optimize and execute immunoassays. Time for assay optimization is often cut from weeks, to a matter of days. This results in increased efficiency in process development and in clinical evaluation of therapeutic proteins. The ease of assay transfer is unsurpassed in the industry.
Gyrolab enables assays to be conducted with a significantly reduced background, increased dynamic range and with higher throughput. All this is achieved using only nanoliter volumes of reagents and sample. More data can be generated in less time and with higher precision, consequently improving productivity and effectiveness. Applications span the entire spectrum for immunoassays and Gyrolab is now firmly established as the preferred solution for pharmacokinetic (PK) assays in the development of therapeutic proteins.
Many major pharmaceutical companies and service providers - CMOs/CROs - have already implemented multiple Gyrolab platforms to boost their drug development process and to meet increasing regulatory demands on testing. Several validated assays are already in some phase of clinical sample analysis. Gyrolab xP complies with the requirements of 21 CFR part 11 and comprehensive validation support is provided.
The company has over 50 employees based at its headquarters in Uppsala, Sweden and at regional sales and support offices in the USA and Europe.